ClinicalTrials.gg
Active, not recruitingNCT07222748Updated Jul 2, 2026

A Study of TLC590 for Postsurgical Pain Following Bunionectomy

A Phase 3 interventional study of TLC590 and Liposomal Bupivacaine in Postoperative Pain, sponsored by TLC Biopharmaceuticals, Inc.. Active, not recruiting at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-02.

Sponsored by TLC Biopharmaceuticals, Inc. · Phase 3, Interventional, and Treatment

Phase
Phase 3
Study type
Interventional
Enrollment
304
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a Phase 3, randomized, double-blind, comparator- and placebo-controlled study to evaluate analgesic efficacy and safety of TLC590 via local infiltration in adult subjects following bunionectomy.

02

Conditions studied

  • Postoperative Pain

Keywords

  • Bunion
  • Bunionectomy
  • Bunion surgery
  • Postoperative pain
03

In context

Pain, Postoperative

5,640 studies on the registry are indexed under Pain, Postoperative; 1,230 are open to participants now.

This study's enrollment of 304 is above the median of 75 across 4,821 interventional studies indexed under Pain, Postoperative.

Browse Pain, Postoperative studies →

Lead sponsor

TLC Biopharmaceuticals, Inc. is the lead sponsor of 2 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able and willing to provide written .
  2. Male or female aged 18 years or older (inclusive).
  3. Scheduled to undergo a primary unilateral, transpositional first metatarsal bunionectomy with osteotomy and internal fixation under regional anesthesia.
  4. ASA Physical Status Classification of 1 or 2.
  5. Male subjects must be either biologically or surgically sterile or commit to the use of a reliable method of (must agree to use double-barrier contraception in the event of sexual activity) or be practicing abstinence.
  6. Female subjects are eligible only if not pregnant, not lactating, not planning to become pregnant during the study, or committing to the use of a highly effective method of birth control.
  7. >18 \~ ≤39 kg/m2, with a minimum weight of 50 kg.

Exclusion criteria

Exclusion Criteria:

  1. An abnormal clinical laboratory test value.
  2. Evidence of a abnormal 12-lead .
  3. History of orthostatic hypotension, syncope, or other syncopal attacks.
  4. History or any clinical manifestation of significant renal, hepatic, gastrointestinal, cardiovascular, metabolic, neurologic, psychiatric, or other conditions that have been assessed by the Investigator to make the subject unsuitable for participation in the study.
  5. History of seizures or taking anticonvulsants.
  6. History of cardiac arrhythmia or taking Class III antiarrhythmic drugs.
  7. History of sleep apnea or at-home CPAP treatment.
  8. History of to ropivacaine, bupivacaine, any other amide-type local anesthetic, or any other trial-required medications.
  9. History of severe or PONV due to other etiologies, including, but not limited to gastric outlet obstruction, hypercalcemia, or active peptic ulcer, deemed clinically significant by the Investigator.
  10. Any lifetime history of a suicidal attempt or any suicidal behavior.
  11. History or positive test results of , , or .
  12. History or current report of substance abuse including illicit drug abuse and/or alcohol abuse.
  13. Positive results on the urine drug screen or alcohol breath test.
  14. Pre-existing concurrent acute, or chronic painful restrictive/physical condition that may confound postoperative pain assessments or is expected to require analgesic treatment during the study.
  15. Has known or suspected daily use of opioids for longer than 4 days per week within 6 months.
  16. Use of daily analgesics for longer than 4 days per week for a chronically painful condition.
  17. Is receiving oxygen therapy.
  18. Use of any of the pre-specified medications prior to the study surgical procedure or as specified.
  19. in the past 2 years, except for non- basal cell or squamous cell carcinoma of the skin or localized carcinoma in situ of the cervix.
  20. Personal or family history of malignant hyperthermia.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
304 participants (actual)

Study arms

  • Experimental
    TLC590

    Drug: TLC590

  • Active comparator
    Liposomal Bupivacaine

    Drug: Liposomal Bupivacaine

  • Placebo comparator
    Saline Placebo

    Drug: Saline Placebo

Interventions

  • DrugTLC590

    TLC590 (Ropivacaine Extended-Release Injectable Suspension)

  • Bupivacaine Liposome Injectable Suspension

  • DrugSaline Placebo

    Normal Saline 0.9%

06

What researchers measure

Primary outcomes

  1. Mean Area Under the Curve (AUC) of the Numeric Rating Scale (NRS) Pain Intensity Scores Through 72 Hours Postsurgery (AUC0-72), Compared with Saline Placebo.

    Pain intensity is measured using an 11-point Numeric Rating Scale (NRS) (0-10), where 0 represents "no pain" and 10 represents "worst pain imaginable", and higher scores indicate worse pain.

    Time frame: 72 hours

Secondary outcomes

  1. Proportion of subjects who are opioid-free for TLC590 compared with Saline Placebo.

    Time frame: 72 hours

  2. Mean Area Under the Curve (AUC) of the Numeric Rating Scale (NRS) Pain Intensity Scores Through 72 Hours Postsurgery (AUC0-72), Compared with Bupivacaine Liposome.

    Pain intensity is measured using an 11-point Numeric Rating Scale (NRS) (0-10), where 0 represents "no pain" and 10 represents "worst pain imaginable", and higher scores indicate worse pain.

    Time frame: 72 hours

  3. Mean Total Postoperative Opioid Consumption for TLC590 Compared with Saline Placebo

    Time frame: 72 hours

  4. Proportion of subjects who are opioid-free for TLC590 compared with Bupivacaine Liposome.

    Time frame: 72 hours

  5. Mean Total Postoperative Opioid Consumption for TLC590 Compared with Bupivacaine Liposome.

    Time frame: 72 hours

07

Study locations

4 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2025 to primary completion in Jun 2026, 6 months.

Of 43 industry-sponsored phase 3 interventional studies under Pain, Postoperative, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 19. This study's 6 months is below that.

Counting every sponsor, half of 166 studies reached it within 17 months; a quarter within 8 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 28, 2025
First posted
Oct 30, 2025
StartActual
Nov 17, 2025
Primary completionActual
Jun 12, 2026
CompletionEst.
Jul 2026
Last update
Jul 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07222748
Lead sponsor
TLC Biopharmaceuticals, Inc.
Responsible party
Sponsor
First posted
Oct 30, 2025
Start date
Nov 17, 2025
Primary completion
Jun 12, 2026
Completion
Jul 2026 (estimated)
Last update
Jul 2, 2026

Study contacts

Tien-Tzu Tai, MD
study director · Taiwan Liposome Company

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ropivacaine

Start the discussion